VX-828
Small molecule
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06154447 NCT06154447 · Cystic Fibrosis Registry: NCT06154447 | 1 | Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 67)); Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 80)); Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 80)); Part E: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Signing of Informed Consent Form (ICF) up to End of Study (Up to Day 111)); Part C: Maximum Observed Concentration (Cmax) of VX-828 in Plasma in the Absence and Presence of Itraconazole (From Day 1 up to Day 71); Part C: Area Under the Concentration Versus Time Curve (AUC) of VX-828 in Plasma in the Absence and Presence of Itraconazole (From Day 1 up to Day 71); Part C: Maximum Observed Concentration (Cmax) of Midazolam in Plasma in the Absence and Presence of VX-828/TEZ/D-IVA (From Day 1 up to Day 30); Part C: Area Under the Concentration Versus Time Curve (AUC) of Midazolam in Plasma in the Absence and Presence of VX-828/TEZ/D-IVA (From Day 1 up to Day 30) 2026-07-10 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (2)
What this study did
What this study did
Competitive landscape
5 other tracked programmes target this mechanism, 5 of them ahead of this one.
This drug's own stage for Cystic Fibrosis: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| VX-828: this drug | Phase 1 | Small molecule | CFTR | not yet graded | No reviewed efficacy summary in this indication | |
| Elexacaftor / Tezacaftor / Ivacaftor (Trikafta) | Approved | Small molecule | CFTR, CFTR | Reliable signal | NCT03525444: Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results). NCT03525548: Absolute change in ppFEV1 from baseline at Week 4 vs tezacaftor/ivacaftor: +10.4 vs +0.4; treatment difference 10.0 percentage points (95% CI 7.4 to 12.6), P<0.0001 (TRIKAFTA label section 14.1; CT.gov posted results). | |
| Ivacaftor (Kalydeco) | Approved | Small molecule | CFTR | Partial signal | NCT00909727: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1) NCT00909532: Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo -0.2 percent of predicted volume (L) (Standard Error 0.7) | 150 mg Ivacaftor q12h 10.4 percent of predicted volume (L) (Standard Error 0.7) | |
| Lumacaftor (Orkambi) | Approved | Small molecule | CFTR | Reliable signal | No reviewed efficacy summary in this indication | |
| Tezacaftor / Ivacaftor (Symdeko) | Approved | Small molecule | CFTR | not yet graded | No reviewed efficacy summary in this indication | |
| Vanzacaftor / Tezacaftor / Deutivacaftor (Alyftrek) | Approved | Small molecule | CFTR, CFTR | Reliable signal | No reviewed efficacy summary in this indication | |
| KB407 | Phase 1 | Gene therapy / editing | CFTR (gene replacement) | not yet graded | No reviewed efficacy summary in this indication | |
| Luvomeran | Discontinued | RNA / oligonucleotide | CFTR (mRNA replacement) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.